ReviewAJR. American journal of roentgenology2016
Current Status of Hybrid PET/MRI in Oncologic Imaging.
Review in AJR. American journal of roentgenology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Staging of esophageal cancer using PET/MRI: a systematic review with head-to-head comparison.BMC medical imaging · 2025Pooled it
- Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review.International journal of nanomedicine · 2022Pooled it
- Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients.Nuclear medicine communications · 2020Pooled it
- Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.PloS one · 2019Trial
- Trial
- Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2018Trial
- The Role of Stromal Tumor Environment in Advancing Skin Cancer Diagnosis and Treatment.International journal of dermatology · 2025Review
- The Application of Combined PET/MRI in Staging and Response Assessment of Rectal Cancer.Journal of clinical medicine · 2025Review
- Radiopharmaceuticals in Malignant Melanoma: A Comprehensive Review of Diagnostic, Therapeutic, and Immune-Related Applications by PET/CT, SPECT/CT, and PET/MRI.Diagnostics (Basel, Switzerland) · 2025Review
- Early Rectal Cancer and Local Excision: A Narrative Review.Journal of clinical medicine · 2024Review
- Peritoneal Carcinomatosis of Malignant Gynecological Origin: A Systematic Review of Imaging Assessment.Journal of clinical medicine · 2024Review
- Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts.European journal of nuclear medicine and molecular imaging · 2023Article
- Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer.Cancers · 2023Article
- FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome.Radiology case reports · 2022Article
- The Performance Comparison ofMolecular imaging and biology · 2022Article
- Estimation of the Internal Dose Imparted byFrontiers in nuclear medicine · 2022Article
- PET/MRI is useful for early detection of pelvic insufficiency fractures after radiotherapy for cervical cancer.Oncology letters · 2021Article
- Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma.Abdominal radiology (New York) · 2021Article
- Head-to-Head Comparison of NeckCancers · 2021Article
- Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis review article explores recent advancements in PET/MRI for clinical oncologic imaging.
conclusionRadiologists should understand the technical considerations that have made PET/MRI feasible within clinical workflows, the role of PET tracers for imaging various molecular targets in oncology, and advantages of hybrid PET/MRI compared with PET/CT. To facilitate this understanding, we discuss clinical examples (including gliomas, breast cancer, bone metastases, prostate cancer, bladder cancer, gynecologic malignancy, and lymphoma) as well as future directions, challenges, and areas for continued technical optimization for PET/MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.